厄洛替尼联合调强放疗治疗晚期肺癌的临床效果观察  

Curative efficacy of erlotinib combined with intensity modulated radiation therapy in treatment of patients with advanced lung cancer

作　　者：费新雄 蒋忠君[1] 张光林[1] 

机构地区：[1]湖北省黄石市中心医院湖北理工学院附属医院肿瘤内科,湖北黄石435000

出　　处：《中国生化药物杂志》2016年第2期37-39,共3页Chinese Journal of Biochemical Pharmaceutics

基　　金：黄石市科技局医药卫生科研立项项目(11)

摘　　要：目的探讨厄洛替尼联合调强放疗治疗晚期肺癌的临床疗效。方法选取110例符合纳入标准的晚期肺癌患者作为研究对象,采用随机数字法分为对照组52例和观察组58例。对照组患者给予调强放疗,而观察组在对照组基础上联合给予厄洛替尼治疗。疗程结束后,比较对照组和观察组患者近期疗效、不良反应及血清血管内皮生长因子(vascular endothelial growth factor,VEGF)、基质金属蛋白酶-2(matrix metalloproteinase-2,MMP-2)和基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)水平。结果疗效评价后显示,观察组近期总有效率明显高于对照组(75.9%vs 57.7%,χ2=4.11,P<0.05)。治疗期间,观察组和对照组患者Ⅰ-Ⅱ度、Ⅲ-Ⅳ度急性放射性肺炎、骨髓抑制、胃肠道反应、肝功能损害等不良反应发生率组间比较差异无统计学意义。治疗后,与对照组相比,观察组患者血清VEGF、MMP-2、MMP-9水平明显降低(P<0.05)。结论厄洛替尼联合调强放疗治疗晚期肺癌能够显著提高近期疗效,降低血清VEGF、MMP-2、MMP-9水平,不良反应发生率无明显增加。Objective To investigate the curative efficacy of erlotinib combined with intensity modulated radiation therapy in treatment of patients with advanced lung cancer. Methods 110 cases with advanced lung cancer meeting the inclusion criteria were collected as research objects. According to therapeutic schemes, those patients were divided into control group （n = 52） and observation group （n = 58）. The control group was given intensity modulated radiation therapy. Besides that, the observation group was given erlotinib additionally. Then, the short-term curative efficacy, toxic side effects and levels of serum VEGF, MMP-2, MMP-9 between two groups were compared. Results After the course of treatment, the short-term curative efficacy ratio in observation group was 75.9% , which was statistically higher than that of 57.7% in control group （X2 = 4. 11, P 〈 0. 05 ）. Adverse reactions, the incidences of Ⅰ - Ⅱ degree and Ⅲ-Ⅳ degree of acute radiation pneumonitis, myelosuppression, gastrointestinal reaction, liver function damage between two groups had no statistical significance. Compared with control group post treatment, the observation group had statistically lower levels of serum VEGF, MMP-2, MMP-9 （P 〈 0.05 ）. Conclusion Erlotinib combined with intensity modulated radiation therapy is effective for patients with advanced lung cancer, which can significantly increase short-term efficacy and reduce levels of serum VEGF, MMP-2, MMP-9 without increasing incidence of adverse reactions.

关 键 词：厄洛替尼 调强放疗 晚期肺癌 血管内皮生长因子 基质金属蛋白酶-2 基质金属蛋白酶-9 

分 类 号：R734.2[医药卫生—肿瘤]